OBJECTIVE： To study the pharmacokinetic change of albendazole （ABZ） in rats after nanocrystallization， and to lay a foundation for further study of ABZ nano-preparation. METHODS： 16 rats were randomly divided into ABZ raw material （ABZ suspension） group and ABZ nano-powder （ABZ nano-powder suspension） group， with 8 rats in each group. They were given relevant medicine 63 mg/kg intragastrically. 0.2-0.3 ml blood samples were collected from orbital cavity 0.5， 1， 2， 4， 8， 12， 24， 36， 48， 72 h after medication， respectively. Using mebendazole as internal standard， blood concentration of ABZ were determined by RP-HPLC， and pharmacokinetics parameters were calculated by using 3p97 software. RESULTS： The pharmacokinetics of ABZ raw material and ABZ nano-powder in rats were in line with two-compartment model. The main pharmacokinetic parameters of ABZ raw material group vs. ABZ nano-powder group were as follows as cmax （3.20±1.41） μg/ml vs. （6.11±0.74） μg/ml； tmax （3.42±0.91） h vs. （3.15±0.27） h； AUC0-72 h （49.90±15.50） μg·h/ml vs. （78.36±8.78） μg·h/ml； AUC0-∞ （52.30±10.10 ） μg·h/ml vs. （80.27±8.26） μg·h/ml. Compared with ABZ raw material group， cmax， AUC0-72 h and AUC0-∞ of ABZ nano-powder group were increased significantly （P＜0.05）. CONCLUSIONS： The nanocrystallization of ABZ can enhance the absorbability rate and improve the absorption of drugs to some extent， and it also improves oral bioavailability of ABZ.